# Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

Study · id `cardio:ct-nct02126358` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02126358](<https://clinicaltrials.gov/study/NCT02126358>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02126358

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 290 participants.

## Technical summary

Registry record NCT02126358. Randomized; quadruple masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2016-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 290 participants (enrolled count; ClinicalTrials.gov record NCT02126358, source copy `cardio:ctgov-nct02126358-2016-10-18`, retrieved 2026-10-26)
- Start date: 2014-05 (registry gives no type) (ClinicalTrials.gov record NCT02126358, source copy `cardio:ctgov-nct02126358-2016-10-18`, retrieved 2026-10-26)
- Primary completion: 2016-03 (actual) (ClinicalTrials.gov record NCT02126358, source copy `cardio:ctgov-nct02126358-2016-10-18`, retrieved 2026-10-26)
- Completion: 2016-03 (actual) (ClinicalTrials.gov record NCT02126358, source copy `cardio:ctgov-nct02126358-2016-10-18`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02126358, source copy `cardio:ctgov-nct02126358-2016-10-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02126358-2016-10-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)
- Condition: Type 2 Diabetes
- Condition: Dyslipidemia
- Intervention (Drug): Gemigliptin and/or Rosuvastatin
- Lead sponsor: LG Life Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: LG Life Sciences (`cardio:org-lg-life-sciences`)

## Provenance

Content hash: adc16461fd2a4f020e56bcca14f3aad276230df0d053b7953c992eddfde48f4e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
